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ABSTRACT
Study Title: Disease Outcome of Oral and Oropharyngeal Squamous Cell 
Carcinoma based on Virological Risk Stratification
Introduction
Oral Cancer is the 9th most common cancer worldwide among men; it is the 6th most common 
cancer in the developing nations. Oral cancer ranks 2nd most common cancer among men in the 
South Central Asia region of which India is a part. In Chennai, head and neck cancers form about 
20% of the cancer burden among men and a little less than 10% among women.  The incidence 
rates of Oropharyngeal and Oral Cancers for men, of the total head and neck cancers, were 10% 
and 45% respectively. Traditional aetiology for head and neck cancers included tobacco and 
alcohol usage. But recently, infection with HPV was found to be an aetiological agent.
Aims and Objectives
The aim of our study was to study the relationship of HPV infection to oral and oropharyngeal cancers. 
We wished to study the association between risk factors of HNSCC and HPV positivity, to evaluate the 
occurrence of premalignant lesions associated with HPV and to study the effect of HPV positivity on the 
aggressiveness of the disease and response to treatment.
Methods and Materials
Based on the literature, we chose to divide the patients into 2 groups – HPV positive and 
negative. Sample size was calculated to be 18 in each group. All patients who were proven 
squamous cell carcinoma of the oral cavity and the oropharynx, treatment naïve and who did not 
have distant metastasis were included in the study. Patients with recurrence/metastasis were 
excluded from the study. Association of premalignant conditions of leukoplakia, erythroplakia 
and submucous fibrosis were looked at in relation to HPV infection. Various factors such as 
tobacco/alcohol use, HPV infection and response to therapy were looked at in oral/oropharyngeal 
cancers.
Results
49 patients were available for HPV analysis, of which 2 patients’ samples tested positive for 
HPV. There was no association found between HPV positivity and response to therapy. Also, 
both patients who were HPV positive had used tobacco. One patient who was HPV positive had 
associated Submucous Fibrosis.
Conclusion
There is need to do more research in this field to clarify the role of HPV in Oral/Oropharyngeal 
Cancers in the Indian setting. Future studies looking at HPV would require having strict 
inclusion criteria. Molecular profiling of these cancers based on p16 and p53 may further shed 
light on this emerging area of research.
Introduction 
 
Cancer is the most common cause of death worldwide, second only 
to heart disease.(1)  Head and neck cancers form a good bulk of the 
cancer burden in developing nations. Whereas oral cancer is the 9th 
most common cancer worldwide among men, it is the 6th most 
common cancer in the developing nations.(1)  Oral cancer ranks 2nd 
most common cancer among men in the south central Asia region of 
which India is a part.(1) 
 
In India, particularly Chennai, head and neck cancers form about 
20% of the cancer burden among men and a little less than 10% 
among women.  The incidence rates of oropharyngeal and oral 
cancers for men, of the total head and neck cancers, were 10% and 
45% respectively.(2) 
 
In recent years, especially in the west, the incidence of head and 
neck cancers is on the decline due to decreased oral tobacco use. 
But a trend of increased incidence of oropharyngeal cancers alone 
was noted.(3)  On further investigation, this was found to be due to 
association with HPV (Human Papilloma Virus).(4) 
 
In India, very few investigators have looked at the relationship 
between HPV and head and neck Cancers.  Elango et al found a 
48% prevalence of HPV among patients with cancer of the 
tongue.(5). Also in a study from the All India Institute of Medical 
Sciences, Delhi, 22% of patients with oropharyngeal cancers were 
found to HPV positive.  They also made a notable observation that 
most of these patients were young and had multiple sexual partners 
which matched the patient cohort of HPV positive oropharyngeal 
cancers worldwide. (6) 
 
. 
 
 
 
 
  
 
 
EPIDEMIOLOGY 
 
 
 
 
 
 
 
 
Epidemiology 
 
Tobacco and alcohol are important risk factors for the majority head 
and neck squamous cell cancers. Approximately 80 % of head and 
neck cancers are attributable to tobacco.(7) Smokers have an 
increased risk of over 10 times of getting head and neck cancer as 
compared to non smokers. (8) Heavy alcohol use is an independent 
risk factor for head and neck cancer.(9)  Also alcohol and tobacco 
have a synergistic effect in causing head and neck cancer. (10). 
 
As alluded to above, there was a decrease in the overall prevalence 
of head and neck cancers and an increase in the prevalence of 
cancers of the oropharynx, leading to the identification of a new 
etiological agent – Human Papilloma Virus (HPV).(4) 
 
The prevalence of HPV related head and neck cancers is on the rise.  
There are varying rates of prevalence reported in literature.  A 
systematic review published in the year 2005 reported HPV 
prevalence as 26% of all head and neck cancers worldwide.(11)  
Among these, Oropharyngeal Cancers had the highest prevalence 
(35%) followed in close succession by Laryngeal (24%) and Oral 
sites (23.5%).(11)  In Asia, the prevalence rates were slightly 
higher.  Oropharynx accounted for 46% of these while Larynx and 
Oral Cavity accounted for 38% and 33% respectively.(11) Among 
the serotypes of HPV identified, 16 and 18 were the most common, 
whereas other oncogenic HPV viruses were rarely discovered.  
HPV 18 was most commonly identified in primaries outside the 
oropharynx.(11)  In India, as already alluded to earlier, Bahl et al 
found the prevalence of HPV in oropharyngeal cancers to be 
22%(6) and Elango et al found the prevalence of HPV in tongue 
cancers to be 48%.(5) 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 ANATOMY  
 
 
 
 
 
Anatomy  
 
The head and neck region has very complex anatomy. Basic 
consideration would be to divide the region into various sub 
divisions namely, Eye and Orbit, Nose and Paranasal sinuses, 
Nasopharynx, Oropharynx, Oral Cavity, Hypopharynx, Larynx and 
Salivary Glands. Some authors also include the Thyroid Gland in 
the anatomical description of the head and neck region. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Oral Cavity 
 
 
(12) 
 
The oral cavity consists of the lips, oral tongue, floor of mouth, 
retromolar trigone, buccal mucosa, and hard palate. 
Figure 1. Anatomy of Oral Cavity 
 The lips begin at the junction of the border with the skin and form 
the anterior aspect of the oral vestibule. They are defined into an 
upper and lower part. The motor control of the lips are supplied by 
the buccal and mandibular branches of the facial nerve. 
 
The oral tongue is mobile and extends anteriorly from the 
circumvallate papillae to the undersurface of the tongue at the 
junction of the floor of mouth. The fibrous septum divides the 
tongue into right and left halves. The oral tongue can be demarcated 
into four anatomic areas: the tip, lateral borders, dorsal surface, and 
undersurface.  
 
There are six pairs of muscles that form the oral tongue. Three of 
these muscles are extrinsic, while the other three are intrinsic. The 
extrinsic muscles are the genioglossus, hyoglossus, and 
styloglossus. The intrinsic muscles are the lingual, vertical, and 
transverse muscles. The extrinsic muscles primarily move the body 
of the tongue, while the intrinsic muscles alter the shape and 
conformation of the tongue during speech and swallowing.  
 The blood supply to the tongue is supplied via the lingual artery, 
tonsillar branch of the facial artery, and the ascending pharyngeal 
artery with primary drainage by the internal jugular vein.  
 
General sensation of the anterior two thirds of the tongue is 
supplied by the lingual nerve.  Taste fibers from the anterior two 
thirds of the tongue run in the chorda tympani branch of the facial 
nerve whereas the glossopharyngeal nerve provides sensation and 
taste to the posterior third of the tongue and circumvallate 
papillae.(13) 
 
The floor of the mouth is a semilunar space extending from the 
lower alveolar ridge to the undersurface of the tongue. The floor of 
the mouth overlies the mylohyoid and hyoglossus muscles. The 
posterior boundary of the floor of the mouth is the base of the 
anterior tonsillar pillar. This region is divided into right and left by 
the frenulum of the tongue and contains the ostia of the 
submandibular and sublingual salivary glands.  
 
A sling formed by the mylohyoid muscles medially supports the 
anterior floor of the mouth, and the hyoglossus supports the 
posterior floor of the mouth.  
 
The lingual and hypoglossal nerves are lateral to the hyoglossus, 
while the lingual artery is medial to the hyoglossus. Innervation of 
the floor of the mouth is provided by the lingual nerve.(13) 
The retromolar trigone is a triangular area which overlies the 
ascending ramus of the mandible. The base of this triangle is 
formed by the posterior molar tooth and the apex lies at the 
maxillary tuberosity of the mandible.(13) 
 
The buccal mucosa includes the mucosal surfaces of the cheek and 
lips from the line of contact of the opposing lips to the 
pterygomandibular raphe posteriorly. This extends to the line of 
attachment of the mucosa of the upper and lower alveolar ridge 
superiorly and inferiorly. Innervation is supplied by the buccal 
nerve, a branch of the mandibular nerve.(13) 
 
 
 
Oropharynx 
 
 
 
(14) 
 
The oropharynx consists of various sub sites such as the posterior 
and lateral pharyngeal wall, tonsillar fossa, soft palate, and the base 
of tongue.(13) 
 
Figure 2. Anatomy of Oropharynx 
The lateral walls of the oropharynx are limited posteriorly by the 
tonsillar fossa proper and the posterior tonsillar pillar. The anterior 
and posterior tonsillar pillars are the folds of mucous membrane 
that cover the underlying glossopalatine and pharyngopalatine 
muscles, respectively.  
 
Deep to the lateral wall of the tonsillar fossa are major vessels and 
muscular components such as the superior constrictor muscle, the 
upper fibres of the middle constrictor muscle, the pharyngeus and 
stylopharyngeus muscles, and the glossopalatine and 
pharyngopalatine muscles. Stratified squamous epithelium covers 
all of these structures. Cranial nerves 9 and 10 supply these 
structures.(13) 
 
The base of tongue lies posterior and inferior to the palatoglossal 
arch. It is bounded anteriorly by the circumvallate papillae, laterally 
by the glossopharyngeal sulci and oropharyngeal walls, and 
inferiorly by the valleculae and the pharyngoepiglottic fold. 
 
Embryologically, its epithelium is derived from the endoderm, 
unlike that from the oral tongue (ectoderm).  
 
The body of the base of tongue is formed by thick muscles, the 
genioglossus, styloglossus, palatoglossus, and hypoglossus muscles. 
The muscles originate from the margins of the mandible and are 
attached to the hyoid bone.  
 
The blood supply and the innervation are by the lingual arteries and 
hypoglossal nerve, respectively.(13) 
 
 
 
 
 
 
 
 
 
 
 
Neck Nodal Levels 
 
Level 1: 
It starts from below the mylohyoid muscle to the lower margin of 
the hyoid bone and remains anterior to the posterior border of the 
submandibular glands 
 
Level IA - submental nodes - between the anterior bellies of the 
digastric muscles 
Level IB - submandibular nodes - posterolateral to the anterior belly 
of the digastric muscles 
 
Level 2: 
It starts from below the base of skull to above the inferior border of 
hyoid bone. It is anterior to the posterior border of 
sternocleidomastoid (SCM) muscle and posterior to the posterior 
border of the submandibular glands 
 
Level 3: 
It starts from the lower margin of hyoid to lower margin of cricoid 
cartilage, anterior to the posterior border of SCM. 
 
Level 4: 
It starts from the lower margin of cricoid cartilage to the level of the 
clavicle, anterior and medial to an oblique line drawn through the 
posterior edge of the sternocleidomastoid muscle and the 
posterolateral edge of the anterior scalene muscle 
 
Level 5: 
It starts from the base of skull up to the level of the clavicles 
posterior to the sternocleidomastoid muscles 
 
Level 6: 
It extends from the inferior margin of the hyoid bone to the 
manubrium sterni, anterior to the levels 3 and 4. 
 
Level 7: 
It extends between the common carotid arteries, inferior to level 6 
and deep to the manubrium 
(15) 
 
  
 
(15) 
 
Figure 3. Lymph Node Levels of the Neck 
  
 
(16) 
 
 
 
 
 
 
Tumour site Level 1 Level 2 Level 3 Level 4 Level 5 
Oral 48 39 31 15 4 
Oropharyngeal 15 71 42 27 9 
Table 1. Incidence and distribution of regional metastasis for levels I-V 
for clinically N+ neck (in percentages) 
 
  
(16) 
 
 
 
 
 
 
 
Tumour site Level 1 Level 2 Level 3 Level 4 Level 5 
Oral 20 17 9 3 0.5 
Oropharyngeal 2 25 19 8 2 
Table 2. Incidence and distribution of regional metastasis for levels I-V 
for clinically N0 neck (in percentages) 
  
 
PATHOLOGY 
 
 
 Pathology  (13) 
The most common type of cancer in the oral cavity is squamous cell 
carcinoma. There are several variants of squamous cell carcinoma 
which include basaloid squamous cell carcinoma and verrucous 
squamous cell carcinoma. Basaloid squamous cell carcinoma is 
believed to have a worse prognosis than traditional squamous cell 
carcinoma. Verrucous carcinoma is generally considered a low-
grade malignancy with low metastatic potential and good overall 
prognosis. (17) Sarcomatoid carcinomas can also be found in the 
oral cavity. These cancers have a poor prognosis with a mean 
overall survival of 2 years. (18) Less than 10% of neoplasms of the 
oral cavity have non squamous histology. Among these, tumours of 
the minor salivary glands are the commonest. Other histologies 
encountered are adenocarcinomas, melanoma, ameloblastoma, 
lymphoma, and Kaposi's sarcoma. 
 
 
 
 
 
  
 
 
 
 
 
 
 
STAGING 
 
 
 
 
 
 
 
 
 
 
 
 
TNM Staging Of Oral Cavity 
 T Stage 
Tx Primary tumour cannot be assessed 
Tis Carcinoma in situ 
T0 No evidence of primary tumour 
T1 Tumour 2 cm or less in dimension 
T2 Tumour more than 2 cm but not more than 4 cm in 
greatest dimension 
T3 Tumour more than 4 cm in greatest dimension 
T4a Tumour invades local structures such as cortical bone, 
into deep muscles of tongue, maxillary sinus or skin of 
face 
T4b Tumour invades masticator space, pterygoid plates, or 
skull base and/or encases internal carotid artery 
 
 N Stage 
Nx Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in a single ipsilateral lymph node 3 cm or 
less in greatest dimension 
N2  
N2a Metastasis in a single ipsilateral lymph node more 
than 3 cm but not greater than 6 cm in greatest 
dimension greatest dimension 
N2b Metastasis in multiple ipsilateral lymph nodes, none 
greater than 6 cm in greatest dimension 
N2c Metastasis in bilateral or contralateral lymph nodes, 
none greater than 6 cm in greatest dimension 
N3 Metastasis in node greater than 6 cm 
 
 M Stage 
M0 No distant metastasis 
M1 Distant metastasis is present 
 
Anatomic 
Staging 
T N M 
Stage 0 Tis N0 M0 
Stage 1 T1 N0 M0 
Stage 2 T2 N0 M0 
Stage 3 T3 
T1-T3  
N0 
N1 
M0 
M0 
Stage 4a T4a 
T1-T4a 
N0-N1 
N2 
M0 
M0 
Stage 4b Any T 
T4b 
N3 
Any N 
M0 
M0 
Stage 4c Any T Any N M1 
(19) 
 
TNM Staging Of Oropharynx 
TX – Primary Tumour cannot be assessed 
 T Stage 
Tx Primary tumour cannot be assessed 
Tis Carcinoma in situ 
T0 No evidence of primary tumour 
T1 Tumour 2 cm or less in dimension 
T2 Tumour more than 2 cm but not more than 4 cm in 
greatest dimension 
T3 Tumour more than 4 cm in greatest dimension or 
extension to the lingual surface of epiglottis 
T4a Tumour invades the larynx, extrinsic muscles of 
tongue, medial pterygoid, hard palate or mandible 
T4b Tumour invades lateral pterygoid muscle, pterygoid 
plates, lateral nasopharynx, or skull base or encases 
carotid artery 
 
 N Stage 
Nx Regional lymph nodes cannot be assessed 
N0 No Regional lymph node metastasis 
N1 Metastasis in a single ipsilateral lymph node 3 cm or 
less in greatest dimension 
N2  
N2a Metastasis in a single ipsilateral lymph node more 
than 3 cm but not greater than 6 cm in greatest 
dimension greatest dimension 
N2b Metastasis in multiple ipsilateral lymph nodes, none 
greater than 6 cm in greatest dimension 
N2c Metastasis in bilateral or contralateral lymph nodes, 
none greater than 6 cm in greatest dimension 
N3 Metastasis in node greater than 6 cm 
 
 M Stage 
M0 No distant metastasis 
M1 Distant metastasis is present 
 
Anatomic 
Staging 
T N M 
Stage 0 Tis N0 M0 
Stage 1 T1 N0 M0 
Stage 2 T2 N0 M0 
Stage 3 T3 
T1-T3  
N0 
N1 
M0 
M0 
Stage 4a T4a 
T1-T4a 
N0-N1 
N2 
M0 
M0 
Stage 4b Any T 
T4b 
N3 
Any N 
M0 
M0 
Stage 4c Any T Any N M1 
(19) 
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Natural history 
 
Premalignant Conditions 
 
Table 3. Premalignant Conditions 
Leukoplakia 
Erythroplakia 
Proliferative Verucous Leucoplakia (VRL) 
Viadent Leukoplakia 
Candida Leukoplakia 
Reverse Smokings’ Palate 
Verrucous Hyperplasia 
Oral Verrucous Carcinoma 
Dyskeratosis Congenita 
Actinic Cheilosis 
Keratoacanthoma 
Oral Submucous Fibrosis 
(20) 
The above list details the number of premalignant conditions 
possible in the oral cavity. We will be dealing with only 3 of these, 
namely – leucoplakia, erythroplakia and oral submucous fibrosis. 
Leukoplakia 
 
The WHO defines leukoplakia as a white patch or plaque that 
cannot be rubbed off or characterized clinically or pathologically as 
any other disease.(21) Leukoplakia is the most common precursor 
of cancer of the oral cavity. It is primarily a clinical entity with 
certain key pathologic features such as hyperkeratosis and 
acanthosis.  There are mainly 2 types – homogenous and non 
homogenous based on appearance. The non-homogenous type has a 
higher malignant potential 
 
Erythroplakia 
 
The term erythroplakia describes a chronic, red, generally 
asymptomatic lesion or patch on the mucosal surface that cannot be 
attributed to a traumatic, vascular, or inflammatory cause. 
Erythroplakia, like leukoplakia, is a clinical diagnosis of exclusion 
that requires the clinician to rule out all other erythematous oral 
lesions.(22) 
 
 
 
Oral Submucous Fibrosis (SMF) 
 
Oral submucous fibrosis (SMF) is a chronic, progressive, scarring, 
precancerous condition which is characterized by mucosal 
roughness and rigidity. It has been causally associated with betel-
nut chewing. SMF is more common in young adults, aged from 
20−40 years. The most frequently involved sites in the oral cavity 
are the buccal mucosa, retromolar area, tongue and soft palate. 
Patients with SMF were at least 19 times more likely to develop 
squamous cell carcinoma compared to the normal population.(23) 
 
Patterns of Spread (13) 
Cancers of the floor of the mouth can involve the ventral tongue 
and extend along the lingual nerve, submandibular duct, or invade 
the cortex of the mandible. They can invade deeply, involving the 
muscles of the floor of the mouth. There is an anatomical gap 
between the mylohyoid and hyoglossus muscles through which a 
cancer can gain access to submandibular and sublingual areas. 
 
Carcinomas of the retromolar trigone tend to invade bone early. 
 Cancer of the buccal mucosa can invade the buccinator muscle and 
extend into the buccal pad of fat, and the subcutaneous tissue. The 
greater palatine foramina can allow tumours to spread posteriorly 
and enter the pterygopalatine fossa and skull base. 
The hard palate has a dense mucoperiosteum and is relatively 
resistant to tumour invasion. However, the primary and secondary 
palates are fused at the incisive fossa and this is where tumours can 
gain access into the nasal cavity. 
 
 
 
 
 
 
 
 
 
 
 
  
 
MOLECULAR 
BASIS OF HPV 
INDUCED 
CARCINOGENESIS 
 
 
Molecular Basis of Human Papilloma Virus induced 
Carcinogenesis 
Human papilloma virus (HPV) is more and more being identified as 
an aetiological agent in head and neck squamous cell carcinomas. 
Human papilloma virus is a non enveloped, double stranded DNA 
virus from the family papillomaviridae. (24) Although most HPV 
serotypes cause benign lesions such as anal warts or genital 
papillomas, a handful of them can cause cancer. As already alluded 
to earlier, the commonest of these are HPV 16 and 18.  
 
A very interesting fact about HPV cancers is it’s relationship to 
p16, which is a cyclin dependant kinase. It is coded by the gene 
CDKN2A (Cyclin Dependant Kinase 2A).  This gene is found to be 
up regulated in HPV related head and neck cancers.(25) p16 has 
been found to be a marker of good prognosis in HPV related 
Oropharyngeal Cancers (26–28),  and has also been identified as a 
surrogate marker for HPV in cases of unknown primary with neck 
nodes (29) and in cervical high grade pre malignant lesions.(30,31) 
 
The viral genomic machinery responsible for carcinogenesis is 
outlined as follows. On the Viral DNA are sections of the genome 
which are responsible for various actions as depicted in the figure 4. 
 
E1-E7 are early open reading frames. They encode for non 
structural proteins responsible for various functions. E1 is 
responsible for episomal DNA replication. E2 is responsible for 
DNA replication and gene expression. It may also lead to repression 
of certain traits. E3 is a misnomer. E4 is responsible for assembly 
and release of viral proteins. E5 are membrane signalling proteins 
which help to relay information from inside the cell to the outside. 
The functions of E6 and E7 are enumerated below 
 
L1 and L2 are late open reading frames and encode for structural 
proteins which are responsible for the viral coat, L1 being for the 
major capsid protein and L2 for the minor capsid protein 
 
 
 
  
 
(32) 
Figure 4. Map of the Human Papilloma Virus Genome 
with their respective functions 
When an oncogenic HPV virus infects a squamous cell, it induces 
the formation of the viral E6 and E7 oncoproteins which lead to 
down regulation of the p53 and Rb (retinoblatoma) tumor 
suppressor genes respectively (Figure 5) and keeps them in a 
dormant state. (33). This releases the Eukaryotic Transcription 
factor 2 (E2F) to cause cell cycle progression.(34)  (Figure 5) 
 
p16 functions as a tumour suppressor by inhibiting cyclin D1 
CDK4/CDK6 complex, preventing phosphorylation of 
retinoblastoma gene and negating the release of E2F resulting in 
cell cycle arrest. When Retinoblastoma gene is turned off by viral 
proteins, p16 activity is upregulated for unknown reasons. (Figure 
2) 
 
HPV positive/p16 positive head and neck cancers have been found 
to have a very favourable prognosis (35)  and are the focus of 
several de intensification treatment regimens. (36) 
 
It has recently been learnt that HPV analysis in recurrent or 
metastatic setting has prognostic significance supporting testing of 
the same in this group of patients.(37,38) 
 
 
 
 
(39) 
 
 
 
 
Fig. 5 Relationship between Retinoblastoma protein and p16 
  
 
 
DIAGNOSTIC 
WORK-UP 
 
 
 
 
 
Diagnostic work-up (13) 
Biopsy of the lesion after a thorough work up needs to be 
performed 
 
Chest Radiograph is taken to rule out metastasis 
 
Computed Tomography (CT) scanning of the head and neck can 
provide accurate details on bony and soft tissue involvement as well 
as assessment of the neck nodes.  It can help in determining the 
extent of invasion into the deep musculature of the tongue and 
adjacent structures. Moreover, CT is a valuable modality for 
visualizing invasion of the mandible, palate, and pterygopalatine 
fossa 
 
X-rays of the mandible can also provide some assessment of 
bony involvement in the absence of CT scan. 
 
Magnetic Resonance Imaging (MRI) of the face and neck is 
indicated when CT scanning will not help in assessment of local 
disease (for e.g., if a patient has a denture). MRI provides excellent 
definition of tumour involving the tongue and is a good modality 
for evaluating the possibility of perineural spread. 
 
Ultrasound Neck can be used to determine the presence of 
enlarged neck nodes which are not clinically detectable. The 
accuracy of ultrasound neck when combined with FNAC (Fine 
Needle Aspiration Cytology) may be superior to MRI or CT 
scanning of the neck.(40) 
 
Positron Emission Tomography-Computed Tomography 
(PET-CT) is a newer modality and has emerged as a one stop 
staging procedure. It has revolutionised the staging, treatment 
planning and follow up of head and neck cancer patients. Its 
strength is in evaluating persistent or recurrent disease, particularly 
in patients who have received previous radiotherapy. 
 
Emerging testing modalities for HPV in HNSCC (41) 
HPV16 E6 DNA Quantitative Polymerase Chain Reaction 
(DNA qPCR): 
Primer and a FAM-MGB labeled Taqman probe are harmonized to 
specifically amplify the HPV L1 region. The test uses fixed 
formalin paraffin embedded tissue. 
 
 
HPV16 E6 RNA Quantitative Polymerase Chain Reaction (RNA 
qPCR): 
Duplicate real-time RNA (complimentary DNA) PCR reactions are 
carried out using the Primer and a FAM-MGB labeled Taqman 
probe to look for the HPV16 E6 gene. The test uses fresh tissue. 
 
 
p16 Immunohistochemistry (IHC): 
p16 is scored as positive if the membrane staining is greater than 
70%. All other staining patterns are termed negative. The test uses 
fixed formalin paraffin embedded tissue. 
 
 
 High Risk HPV In Situ Hybridisation (HR HPV ISH): 
High risk HPV in situ hybridisation is carried out using proprietary 
reagents. It can detect various high risk genotypes (16, 18, 
31, 33, 35, 39, 45, 51, 52, 56, 58 and 66).The test was scored as 
positive if there was any blue reaction product that co localised with 
the nuclei of malignant cells. The test uses fixed formalin paraffin 
embedded tissue. 
 
The above tests have been evaluated in a prospective study by 
Schache et al.(41) The best combination of testing was to use HPV 
qDNA PCR along with p16 which gives a sensitivity and specificity 
of 97% and 94% respectively, compared with the gold standard of 
HPV RNA qPCR (Table 4). Other testing combinations did not give 
adequate sensitivity and specificity.  Smeets et al. used p16 IHC as 
an initial screening test and followed it up with HPV DNA qPCR 
on the positive samples and found a sensitivity and specificity of 
100%. (42) 
 
 
 
 
  
 
 Sensitivity Specificity Statistical 
Significance 
HPV 16 status by RNA 
qPCR (Gold Standard) 
(compared to RNA 
qPCR) 
 
p16 IHC 0.94 0.82 <0.001 
HR HPV ISH 0.88 0.88 0.001 
Combined p16/HR 
HPV ISH 
0.88 0.90 0.001 
DNA qPCR 0.97 0.87 0.02 
Combined p16/DNA 
qPCR 
0.97 0.94 0.002 
Combined p16/RNA 
qPCR 
0.94 1 0.008 
Combined DNA 
qPCR/RNA qPCR 
0.94 1 0.001 
(41) 
 
Table 4. Sensitiviy and Specificity of the Various Test/Test 
Combinations for HPV 
  
 
 
 
 
PROGNOSTIC 
FACTORS 
 
 
 
 
 
Prognostic factors 
 
Lymph node positivity is the single most adverse prognostic factor 
for head and neck squamous cell carcinoma.(43) 
 
Several pathological factors in the primary tumour are associated 
with poor prognosis. 
 
Tumour thickness and depth of invasion have been shown to be 
associated with a higher risk of regional metastases. (17) 
 
 Perineural invasion has correlated with neck node metastases, extra 
capsular extension, and diminished survival. (44) 
 
 Vascular invasion has correlated with positive cervical lymph node 
metastases, (45) but not lymphatic invasion.(17)  
 
The prognostic significance of grade has also been looked at and 
has not been found to an independent prognostic marker. (17) 
 
 
(46) 
(46) 
 
 
 
 Disease Specific 
survival (5 year) 
Percentage 
Overall survival 
(5year) Percentage 
Pathologically N0 88 % 75 % 
Pathologically N+ 65 % 50 % 
Pathologically N+ 
with ECE 
48 % 38 % 
Table 5. Relationship between the occurrence of 5 year 
disease specific and overall survival in relation to the post 
operative nodal status of 266 oral squamous cell 
carcinomas of the tongu   
 
 Disease Specific 
survival (5 year) 
Percentage 
Overall survival 
(5year) Percentage 
Pathologically N0 88 % 75 % 
Pathologically N+ 65 % 50 % 
Pathologically N+ 
with ECE 
48 % 38 % 
 Relationship between the occurrence of 5 year disease specific and 
overall survival in relation to the post operative nodal status of 266 oral 
squamous cell carcinomas of the tongue  
  
 
 
PRINCIPLES 
OF SURGERY 
 
 
 
 
Principles of Surgery 
Surgery is the mainstay of treatment in early stage oral cancer. It 
involves resection of the primary lesion, appropriate mandibular 
resection where necessary and reconstruction as needed. 
 
Reconstruction may be in the form of primary closure, skin graft, 
regional flap, or free tissue transfer from different sites. These are 
decided based on the anticipated tissue loss, expertise of the 
surgeon and facilities available for the same.(47) An appropriate 
neck dissection is also performed. It can be a selective neck 
dissection, a Modified Radical Neck Dissection (MRND), Radical 
Neck Dissection (RND) or an extended neck dissection.  
 
Standard radical neck dissection involves removal of the superficial 
and deep cervical fascia with its lymph nodes from levels I to V in 
continuity with the sternocleidomastoid muscle, omohyoid muscle, 
internal and external jugular veins, spinal accessory nerve, 
glossopharyngeal nerve and submandibular gland.  
Modified radical neck dissection removes the superficial and deep 
cervical fascia with its enclosed lymph nodes and leaves one or 
more of the non lymphatic structures such as the 
sternocleidomastoid and digastric muscles, internal jugular vein, 
and spinal accessory nerve/glossopharyngeal nerve.  
 
In selective neck dissection, one or more of lymph node groups I to 
V are not removed. There are various types – Supra omohyoid neck 
dissection and lateral neck dissection.  
 
Supra omohyoid neck dissection removes the lymph nodes in levels 
I to III and is most commonly used for patients with small oral 
cavity cancers and a clinically node negative neck 
 
The lateral neck dissection includes removal of level II to IV nodes 
and is often used for laryngeal, oropharyngeal, and hypopharyngeal 
cancers. 
 
An extended radical neck dissection involves removal of additional 
lymph node groups or non lymphatic structures in addition to other 
structures removed while doing a radical neck dissection 
 
 
 
 
 
 
 
  
 
 
PRINCIPLES OF 
RADIOTHERAPY 
 
 
 
 
Principles of Radiotherapy  
Radical radiotherapy is a viable option for the treatment of early 
oral and oropharyngeal cancers.  
 
In case of oral cancers, some or all of the treatment needs to be 
administered with the help of brachytherapy to improve 
outcomes.(48) In a study done by Pernot, they reported local control 
rates of 96% for T1, 85% for T2, and 64% for T3 lesions of the oral 
cavity treated with brachytherapy/neck dissection. In the same 
series, local regional control rates were 83%, 70%, and 44%, 
respectively.(49) Advanced lesions require combined modality 
treatment – surgery and radiotherapy.  
 
Although radiotherapy can be given as both neo adjuvant as well as 
post operative, post operative is preferred. (48,50). There are 
advantages with the post operative approach – no radiotherapy dose 
limitation, no delay in planned surgical resection, and complete 
pathologic staging of the tumour. 
 
  
 
 
PRINCIPLES OF 
CHEMOTHERAPY 
 
 
 
Principles of Chemotherapy  
Concurrent chemotherapy has been the standard of care in locally 
advanced head and neck squamous cell cancers for the past decade. 
Several meta analysis (51,52) have shown the benefit of concurrent 
chemo irradiation. Although the designs of the trials included in the 
meta analysis were different, the basic comparison of radiotherapy 
in one arm with radiotherapy and concurrent chemotherapy in the 
other arm were made. The overall survival benefit quoted in the 
literature ranges from 1% - 8%. (53)   
 
Neo adjuvant chemotherapy has not been the standard of care in 
oral cancers. A study done by Licitra et al found that overall 
survival was not changed with neo adjuvant chemotherapy but that 
the respectability and need for post op radiotherapy was 
reduced.(54)  
 
The role of chemotherapy along with post op radiotherapy has been 
looked at. Two trials, one from Europe (EORTC) and another from 
USA have looked at this question. The inclusion criteria were 
slightly different. In general, they found that microscopically 
positive margins, more than 2 nodes positive and extra nodal 
deposits, were associated with a better disease free survival if 
chemotherapy was added to radiotherapy. There was no benefit in 
overall survival in the American study while the EORTC trial 
showed both progression free survival as well as overall survival. 
(55,56) 
 
Neo adjuvant chemo irradiation has not been adopted widely due to 
the prohibition of maximum radiotherapy dose to be administered. 
Also the chance of wound breakdown post surgery is a very likely 
possibility. A study done by Mohr et al. showed that pre operative 
chemo irradiation increased the overall survival and local control 
with the preoperative regimen but the regimen used was not very 
standard and was not convenient. They used 36 Gy at 2 Gray per 
fraction with concurrent Cisplatin 12.5 mg/m2 on the days of 
radiotherapy.(57) 
 
  
 
RADIOTHERAPY 
TECHNIQUES 
 
 
 
 
 
Radiotherapy Techniques  
Conventional Radiotherapy uses parallel opposed lateral portals 
to cover the tumour and regional lymphatics. An anterior neck field 
is used in most cases to cover the pre tracheal nodes. After 40 Gy, 
spine shielding is done to limit the dose to the spinal cord. If 
required, the level 5 nodes are boosted up to 50 – 60 Gy with 
electrons, depending on the initial nodal burden. After 50 Gy, a 
shrinking field technique is applied and the primary and positive 
nodes are boosted to a maximum of 66 Gy. 
 
3D Conformal Radiotherapy uses the same principles as 
conventional radiotherapy, but the field arrangements are different 
and dose to organs at risk are noted and kept to a minimum. 
 
Intensity Modulated Radiation Therapy is a technique where 
the beams are modulated with the help of multileaf collimators as 
well as dynamic wedges, to produce a conformal dose distribution 
around the primary tumour and draining lymphatics with a margin. 
GTV (Gross Tumour Volume), CTV (Clinical Target Volume) and 
PTV (Planning Target Volume) are contoured. The OAR’s are 
contoured. The dose to each structure is determined and the plan is 
approved according to set constraints. 
 
 
 
 
 
 
 
 
 
 
  
DISEASE 
OUTCOME 
 
 
 
 Disease outcome  
In general, the disease outcome in HPV negative tumours is dismal.  
 
Weinberger et al found that disease free survival and overall 
survival was improved in patients of oropharyngeal cancers with 
HPV and p16 positivity. (58) But this study also showed that HPV 
positive and p16 negative tumours had no difference in disease free 
survival and overall survival as compared to HPV negative 
tumours.  
 
Another study done which looked at multiple factors affecting 
overall survival and disease free survival found that HPV positive 
tumours had improvement in both these parameters.(59)  
 
A number of factors have been postulated to explain the improved 
survival with HPV positive tumours. These are improved radio 
sensitivity of these tumours,(60,61)  immune surveillance of viral 
antigens and absence of field cancerization because of most of these 
tumours are present in individuals who have never had tobacco or 
alcohol use.(62,63) 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
AIM 
 
 
 
 
 Aim 
 
The aim of our study is to study the relationship of HPV infection to oral 
and oropharyngeal Cancers. 
 
 
 
 
 
  
OBJECTIVES 
 
 
Objectives 
 
To study the association between risk factors of head and neck 
squamous cell cancers and HPV positivity  
 
To evaluate the occurrence of premalignant lesions associated with 
HPV. 
 
To study the effect of HPV positivity on the aggressiveness of the 
disease and response to treatment  
 
 
 
 
 
 
 
 
  
 
 
METHODS 
AND 
MATERIALS 
 
Methods and Materials 
 
Patients were recruited using suitable inclusion and exclusion 
criteria from the OPD’s of the departments of Radiotherapy, ENT, 
General Surgery Unit 1 and Dental Surgery. 
 
Inclusion Criteria 
Pathological: Patients with pathologically proven squamous cell carcinoma of 
the oral Cavity and oropharynx of age above 18 years (adults) 
Clinical Stage: Any T, Any N without distant metastasis or recurrence as 
determined by clinical evaluation [Includes History, Physical examination 
and Nasopharyngolaryngoscopy{NPL Scopy}/Direct LaryngoScopy {DL 
Scopy}] and Imaging. 
 
Exclusion Criteria: 
1. Metastatic or recurrent Disease. 
2. Adequate tumour tissue not available for assessment due to prior 
biopsy/excision at an outside centre. 
3. Any prior therapy received for the malignancy for which the patient 
is presenting at present. 
4. Pregnant women. 
Metastatic or recurrent cancers were excluded because of data 
stating that patients with HPV positive cancers in this cohort of 
patients had similar outcome to HPV negative patients. (64) 
 
Procedure 
 
Once a potential patient was identified by clinical and/or imaging features 
or with an outside biopsy of squamous cell cancer, he/she along with the 
relatives are counselled regarding inclusion in the study and informed 
consent is obtained. Once informed consent was obtained, biopsy of the 
suspected lesion was done in the Department of Dental and Oral Surgery 
(Oral Malignancy) or Department of ENT (Oropharyngeal Malignancy).  
 
At the time of biopsy, 2 containers were required: 
1. Standard formalin histopathology specimen which was sent to 
General Pathology Lab 
2. Small cold chain specimen container with reagent for HPV analysis 
(25mg, 0.4x0.4 cm size) which was sent to Clinical Virology Lab.  
 If the biopsy was conclusive of squamous cell carcinoma, staging work up 
was done. If biopsy was inconclusive, a second biopsy was done. If the 
second biopsy was also inconclusive or negative for squamous cell 
carcinoma and/or the staging workup was positive for metastasis, then the 
patient was excluded from the study.  Once all work up, dental clearance 
and cardiology clearance was completed, patient proceeded for treatment 
based on the site and stage of disease. 
 
Following completion of treatment, patients were followed up every 3 
months for a year. 
 
Assessment Variables 
 
The presence of the various risk factors for HNSCC were recorded 
1. Smoking  
2. Pan Chewing (smokeless tobacco) 
3. Alcohol 
 
The history of sexually transmitted disease was recorded 
 
The presence of the following pre malignant lesions were recorded. 
1. Leukoplakia 
2. Erythroplakia 
3. Submucous Fibrosis 
 
The presence of residual/local recurrence, regional and distant 
metastasis was looked at in relation to HPV negative and HPV 
positive patients. 
 
Treatment 
 
Radical Surgery (Oral Cancers) included a wide excision of the 
primary tumour + appropriate reconstruction and ipsilateral supra 
omohyoid node dissection (level 1-3) in clinically node negative 
disease and radical/modified radical neck dissection (level 1-5) 
when nodes were clinically palpable.  
 
Radiotherapy in the Post Operative setting was given if the 
following conditions were fulfilled 
1. Large primary - T4 or T3 with soft tissue infiltration 
2. Close margins of excision 
3. Deep infiltrative tumour 
4. Lympho-vascular and perineural invasion 
5. Bulky nodal disease N2 / N3 
 
Indications for addition of chemotherapy to radiotherapy was  
1. Presence of extranodal deposits  
2. Positive surgical margins. 
 
Radiation doses to be used for Radical and Post Op settings was 
given 60 – 66 Gray at 2 Gray per fraction to the Primary disease (5 
– 6 days a week) and 46 – 50 Gray for the prophylactic lymph nodal 
area (5 - 6 days a week).  
 
 
 
Concurrent chemotherapy was planned as follows:  
Inj. Cisplatin was administered (40mg/m2) once weekly for a 
maximum of 4 cycles.  
Or 
Inj. Cisplatin was administered (100mg/m2) once every 3 weeks for 
a total of 2 – 3 cycles based on tolerance. 
 
Palliative Radiotherapy was executed with radiation doses of 40 
Gray in 10 fractions to the primary and draining lymph node areas 
at highest risk of disease (2 fractions a week).  
 
Patients were reviewed weekly during Radiotherapy for potential 
reactions or more frequently if required. They were also advised to 
use regular mouth washes and vitamins during the period of 
radiotherapy and for 4 – 6 weeks afterward. If necessary, Ryle’s 
tube feeding and nutritional advice were initiated if deemed 
appropriate by the treating physician. 
 
HPV status by DNA PCR and RNA PCR 
 
These methods are described in detail as follows: 
 
Sample collection:  
 Biopsy tissue in viral transport medium was collected and 
transported in an ice container. 
 Viral transport medium: Balanced isotonic solution at 
physiological pH. It maintains the virus in the viable state. 
Generally contains fetal calf serum and antibiotics. 
 Once received, the sample is transferred to a 1.5ml 
eppendorf tube and stored at -800C until further testing. 
 
DNA Extraction protocol 
DNeasy® Tissue kit: (Qiagen GmbH, Hilden, Germany) 
Principle: Column based separation. 
 Tissue is cut into small pieces weighing 25mg and it is 
digested by adding ATL buffer and Proteinase K at 56C. 
 Once digested, an equal amount of AL (Lysis buffer) buffer 
and Ethanol is added. 
 The DNA gets precipitated and its washed twice by adding 
buffers (AW1 and AW2) 
 The DNA is then eluted by adding elution buffer. 
 The extract (containing the DNA) is stored at -20C until 
further testing. 
 
PCR: 
 A known positive control is used for PCR and beta-globin 
serves as internal control. 
 Primers used: a) PGMY 09/11: Target size: 450 base pair. 
            b) PCO4/GH20 (Beta-globin): 230 base pair 
 A sample can be analyzed only if the beta globin is positive.  
 Based on the presence or absence of target band (450bp), the 
sample is interpreted as positive or negative. 
 
Sequencing: 
 
 If sample is positive for HPV, the amplified PCR products 
will be purified by Millipore filtration and sequenced 
directly using an ABI Prism Big Dye terminator cycle 
sequencing ready reaction kit. 
  After a post-sequencing clean-up by Millipore filtration, the 
sequencing reactions will be run on an ABI PRISM 310 
genetic analyzer (PE Applied Biosystems, CA, USA).  
 Finally, the data will be analyzed using Bioedit software 
version 7.0.5.3 and study sequences compared to the 
GenBank HPV sequences. 
 
RNA Extraction and Amplification by Real Time PCR:  
Studies for mRNA will be done by Ambion RNA extraction 
protocol. Principle is column based separation. E6 and E7 mRNA 
oncogene expression reflects a direct viral involvement in the 
carcinogenesis. Amplification of HPV 16 and 18 will be done 
using real time PCR based on Taqman chemistry. Primers and 
probes will target the E6/E7 region of HPV 16 genome (80-120 
base pairs). Similarly, the E7 region of HPV 18 will be chosen for 
quantitation. 
 
Isolation of Genomic DNA: 
Fresh tissue collected at the various OPD’s will be transported in a 
viral transport medium. DNA will be extracted using the DNeasy® 
Blood and tissue kit (Qiagen GmbH, Hilden, Germany). The 
extraction protocol followed as per the manufacturer instructions. 
 
HPV PCR: 
HPV L1 region will be amplified using PGMY 09/11 primers. 
PC04/GH2O was used as the internal control (Housekeeping gene) 
to check for the integrity of the sample. 
 
 
 
 
(65) 
Figure 6. Schematic representation of different primer sets for HPV DNA 
detection. Primers targeting the L1 gene of HPV are the most widely used. 
The PCR will be carried out as a single step non-nested PCR. These 
universally used primers would detect most of the oncogenic HPV 
types including HPV 16 and 18. Detection of the amplified products 
will be carried out by electrophoresis in an ethidium bromide 
stained 2.5 % agarose gel. Presence of a 450 base pair HPV DNA 
specific product and a 230 base pair beta globin specific product 
indicates a positive result. PGMY09/11 is a set of consensus 
primers which has higher sensitivity, specificity and reproducibility. 
(66) 
 
The cycling conditions in the PCR are 95oC, 10min followed by 40 
cycles of 95oC, 1min; 55oC, 1min and 72oC, 10min and a final 
elongation step of 72oC, 10min.  
 
The thermal cyclers to be used for PCR are  
a) Veriti TM Thermal Cycler (Applied Biosystem, Foster City, 
California, USA). 
b) GeneAmp® PCR system 9700 (Applied Biosystem, Foster 
City, California, USA). 
  
 
 
 
 
 Sample size 
 
Class I: HPV negative, p16 low; 5 yr local recurrence: 45% 
Class II: HPV positive, p16 low; 5 yr local recurrence: 74% 
Class III: HPV positive, p16 high; 5 yr local recurrence: 14% 
Sample size calculation: (outcome vs. local control at 5 yrs) 
These values were obtained from the study done by Weinberger et 
al. (58) The local recurrence rates of classes I and II were clubbed 
and compared to the recurrence rate of class III as class III 
represented a molecular and virological true model of HPV. Class 
II, even though being HPV positive, had a worse outcome than the 
other 2 groups and was more similar to the HPV negative group. 
Hence, it was clubbed together with it for sample size analysis. 
There is data to support that Tobacco and alcohol usage may 
downplay the beneficial effects of being HPV positive and hence a 
distinction may be seen.(67) 
 
 
The following formula was used for calculation of sample size 
 N= 2 p’q’ (Zα + Zβ)2 / (p1-p2)2  
p1= recurrence rate of class III = 14% (approx) 
p2= recurrence rate of class II and I = 60% (approximately 74+45/2) 
p’= (p1+p2)/2 = 37 
q’= 100-p’ = 63 
Zα = type I error = 1.96 at 5% level 
Zβ = type II error = 0.84 for β=20% 
This gives a value of 17.27 (approx. 18) 
So sample size would be 18 in each group. 
 
 
Analysis 
 
The data was entered in Epi Data Software Entry Tool (Version 3.1) 
and analyzed using SPSS software Version 15. 
 
 
 
  
 
 
 
 
 
 
 
 
 
RESULTS 
 
 
 
 
 
 
 
 
 
 Results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
52 patients were recruited 
2 patients excluded because histology was 
DLBCL (Diffuse Large B Cell Lymphoma) 
1 patient’s sample could not be retrieved 
49 patients’ biopsy 
specimen available for 
analysis 
41 patients available for response 
assessment 
29 patients available for follow up 
analysis 
49 patients available for 
demographical and clinical assessment 
  
 All Patients (%) 
Age (in Years)  
Median 56 
Range 25 – 78  
TNM Stage  
1 5 (10.2) 
2 5 (10.2) 
3 13 (26.5) 
4 26 (53.1) 
T stage  
T1 8 (16.3) 
T2 12 (24.5) 
T3 11 (22.4) 
T4 17 (34.7) 
N stage  
N0 16 (32.7) 
N1 17 (34.7) 
N2 14 (28.6) 
 2 (4.1) 
 
 
Table 6 
Demographic and Clinical Variables 
  
Duration of Symptoms (in months)  
Range  2 – 12   
Mean 3 
Management  
Surgery +/- Radiotherapy 25 (51) 
Radiotherapy +/- Chemotherapy 16 (32) 
No Treatment 8 (17) 
Tobacco Smoking  
Yes 23 (46.9) 
No 26 (53.1) 
Tobacco Chewing  
Yes 25 (51) 
No 24 (49) 
Alcohol Consumption  
Yes 13 (26.5) 
No 36 (73.5) 
Haemoglobin (n=48)  
Range 9.4 – 15.9 
Mean 13.2 
 
 
Table 6 (contd.) 
Demographic and Clinical Variables 
  
Site  
Oral Cavity 28 (57) 
Oropharynx 20 (41) 
HIV status  
Negative 48 (98) 
Positive 0 (0) 
Not available 1 (2) 
Previous Sexually Transmitted 
Disease 
 
Yes 1 (2) 
No 48 (98) 
Previous Anal/Gynaecological 
Malignancies 
 
Yes 0 (0) 
No 49 (100) 
Co morbidities  
Yes 23 (46.9) 
No 26 (53.1) 
 
 
 
Table 6 (contd.) 
Demographic and Clinical Variables 
  
 
 
 
 
 
77.6
22.4
Sex (%)
Male (38)
Female (11)
Figure 7. Sex Distribution 
  
 
 
N = 49 Oral Cavity (%) Oropharynx (%) 
Total 28 (57) 21 (43) 
 
 
 
35%
25%2%
14%
6%
8%
4%
6%
Site (%)
Tongue (17) Base Of Tongue (12)
Floor Of Mouth (1) Buccal Mucosa (7)
Alveolus (3) Tonsil (4)
Soft Palate (2) Posterior Pharyngeal Wall (3)
Figure 8. Site Distribution 
  
 
 
 
46.9
10.2
18.4
20.4
4.1
Occupation (%)
Manual Labourer (23)
Farmer (5)
House wife (9)
Others (10)
No data (2)
Figure 9. Occupation Distribution 
  
 
 
 
98
2
ECOG Performance status (%)
1 (48)
3 (1)
Figure 10. Performance Status 
  
 
 
 
85.7
6.1
4.1
4.1
Education (%)
School (42)
UG (3)
PG (2)
Missing (2)
Figure 11. Education 
  
 
 
 
 
Pre Malignant Lesions (%)
 Submucous Fibrosis (1)
Leucoplakia (1)
Nil (47)
Figure 12. Pre Malignant Lesions 
  
 
 
 
 
10.2
10.2
26.5
53.1
TNM Stage (%)
1 (5)
2 (5)
3 (13)
4 (26)
Figure 13. TNM Stage Distribution 
  
 
 
 
 
4.1
95.9
Human Papilloma Virus (%)
Positive (2)
Negative (47)
Figure 14. Human Papilloma Virus (HPV) Distribution 
The median follow up duration was 3 months (Range: 1 – 12 
months). The clinical and demographic details are enumerated in 
Table 6.  
 
The number of patients who underwent surgery as part of their 
management protocol was higher as compared to radical 
radiotherapy 
 
There was no difference found between HPV positive and HPV 
negative patients in terms of age, sex, history of sexually 
transmitted disease or tobacco/alcohol usage. 
 
 
 HPV positive  HPV negative   
Tobacco/Alcohol present                      2                36  
Tobacco/Alcohol absent  0  11  
Table 7. Relationship between HPV and Tobacco and Alcohol 
Usage 
Performance score was recorded using the ECOG model.(68) It was 
not analyzed separately as there was only one patient with an 
ECOG performance score of 3 and all others had a performance 
score of 1. 
 
There was one HPV positive patient who had associated submucous 
fibrosis. (Table 8) Otherwise no other relationship could be made 
out between HPV positive and HPV negative patients. This was not 
found to be statistically significant. 
 
 
 HPV Positive HPV Negative 
Sub Mucous Fibrosis 1 0 
Leukoplakia 0 1 
Nil 1 46 
 
 
Table 8. Relationship between HPV and Pre Malignant Lesions 
 Only 29 patients had follow up data recorded. Residual disease at 6 
weeks and local recurrence at 3 months was found in 11 patients, of 
which 1 patient was HPV positive. (Table 9)  Regional and Distant 
Failure was found in 2 of the HPV negative patients and none of the 
HPV positive patients.  This was not found to be statistically 
significant. 
 
 
 HPV positive HPV negative 
Local 
Recurrence/Residual 
Disease 
1  10  
Failure 
(Regional/Distant) 
0 2 
Disease Free 1 15 
 
Only the L1 portion of HPV capsid protein was identified in 2 
patients (DNA qPCR). (Figure 12) There was no serotype specific 
HPV 16 and 18 E6 and E7 gene sequences amplified on RNA qPCR. 
 
Table 9. Relationship between HPV and disease outcome 
A descriptive analysis of these patients has been carried out. 
 
The first patient was a 47 year old male from West Bengal, who was 
an office worker and had done undergraduate studies. He had 
duration of symptoms for 7 months. He was a regular tobacco 
chewer for the past 10 years.  He did not use alcohol or smoke 
cigarettes. He had no history of sexually transmitted disease. He had 
no family history of malignancy. On evaluation, he was found to 
have Carcinoma Buccal Mucosa Stage 1 (T1N0M0) with associated 
sub mucous fibrosis. He had no co morbidities. He underwent 
surgery (wide local excision + Right Modified Radical Neck 
Dissection). The post op histopathology report was favourable. He 
was kept on follow up. He was disease free at last follow up at 6 
months. 
 
The second patient was a 56 year old man from Tamil Nadu who 
was a manual labourer, and had studied till class 10. He had duration 
of symptoms for 2 months. He was a regular smoker of cigarettes 
and used to consume alcohol frequently. He did not chew tobacco. 
He had no history of sexually transmitted disease. He had no family 
history of malignancy.  He was diagnosed to have Carcinoma Soft 
Palate Stage III (T3N0M0). He had co morbidities of Diabetes 
Mellitus on oral hypoglycaemic agents. He underwent radical chemo 
irradiation. This patient had multiple breaks during radiotherapy (due 
to personal reasons) and gap correction was done to achieve a 
tumoricidal dose without the negative effects of stopping treatment 
midway (accelerated repopulation). He finally received 46 Gy in 23 
fractions at 200 cGy/fraction followed by 23.4 Gy in 12 fractions at 
195 cGy/fraction, finally achieving a total tumour dose of 69.3 Gy in 
35 fractions, with spine shielding at 40 Gy and field size reduction at 
49.9 Gy (25 fractions). He also had only 1 cycle of weekly Cisplatin. 
No further cycles were given as patient had poor tolerance due to 
grade 3 mucositis and low counts. Assessment at end of treatment 
revealed residual disease. This was not biopsy proven.  He came for 
follow up after 2 months and then was lost to follow up. Residual 
disease had increased in size at that time. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
 
 
 
 
 
 
 
 
Discussion 
 
In this cohort, there were a large number of patients who used 
tobacco or alcohol. About 47% of the patients smoked cigarettes, 
51% chewed tobacco and 27% of the patients consumed alcohol. 
When taken together as a group, 78% (n=38) of the patients used 
one of these substances and 11 patients (22%) had no history of 
substance abuse.  
 
p16 is known to be associated with good prognosis in HNSCC. 
(28,69) p53, also known as the guardian of the genome, has a 
beneficial role to play in the pathogenesis of HNSCC. 
 
It is a known fact that tobacco and alcohol use cause the proposed 
beneficial effect of being HPV positive to become negated. (58,67) 
This is because p16 (a cyclin dependant kinase) is down regulated 
due to several distinct and exclusive events such as homozygous 
deletion, point mutation, and promoter methylation.(67) p53 
mutation also happens in this situation. The combined effect results 
in decreased responsiveness of the tumour to standard treatment. 
(58) Thus outcome associated with the HPV positive patients who 
used tobacco or alcohol would be similar to the HPV negative 
group or even worse.(58) Both patients who were HPV positive 
used some form of tobacco. Concerning response to treatment, one 
patient had a good response to treatment while the other patient did 
not have. The reasons for these are not related to HPV but rather to 
stage and treatment factors. As mentioned in the results section, one 
patient had early stage cancer and underwent radical surgery He had 
no local recurrence at last follow up, while the other patient who 
underwent radical chemo irradiation but had irregular treatment had 
poor local control. It is well known that squamous cell cancers of 
the head and neck region are very aggressive tumours and undergo 
accelerated repopulation if the treatment is not completed within 7-
8 weeks, leading to poor local control. (70–72).  
 
One of the patients with oral buccal mucosa cancer with HPV 
positivity had associated submucous fibrosis (SMF). There is sparse 
data in the literature about the relationship between HPV and 
submucous fibrosis.(73–75) Luo et al suggested that oral SMF is 
associated with low risk HPV serotypes (LR HPV) (other than 16 
and 18). Mehrotra et al, in a study done from Allahabad, could not 
find any correlation between high risk HPV (HR HPV) serotypes 
and oral SMF. Subsequently Jalouli et al found a HR HPV 
prevalence of 91% in oral SMF. But the findings of Jalaouli did not 
correlate with the above 2 studies. Our patient was found to have 
HPV positivity (L1 portion of HPV capsid protein was detected), 
but his E6/E7 RNA gene amplification for HPV 16 and 18 was 
negative implying he had a serotype other than HPV 16 and 18. 
 
As alluded to earlier, there was scanty number of HPV positive 
cancers discovered. The reasons for this are multiple and are 
discussed below. 
 
The total number of oral cancers was more than oropharyngeal 
cancers. It is known that oropharyngeal cancers have higher 
association with HPV than other head and neck subsites.(11,76,77) 
It was decided to add on the other sites as prevalence data had 
shown HPV positivity to be between 23% - 48% (6,11) in oral 
subsite as well. This may have contributed to the less number of 
HPV positive cancers detected. Also, it is well known that HPV 
positive head and neck cancers are more in the tonsillar subsite of 
the oropharynx.(27,78,79)The number of tonsillar cancers included 
in this study were minimal (8%, n=4), and may have contributed to 
the low HPV positivity. 
 
The age of the patients were wide spread with most of the patients 
being more than 50 years (70%). This also goes against the well 
known fact that most of the patient with HPV positive HNSCC are 
from the younger age group. (35,80). Hence, this may be a reason 
for the poor positivity of HPV in our cohort group. 
 
Clinically, HPV positive cancers present with a small primary and 
large cervical lymph nodes. This was not seen in the 2 patients who 
were HPV positive. This may be explained by the fact that our 
patients did not represent the molecular profile of good prognosis 
HPV cancers because of the presence of tobacco and alcohol, down 
regulating p16.(58) 
 
Only 1 patient gave history of previous sexually transmitted disease 
and this patient was not HPV positive. Moreover he was also a 
smoker and alcohol consumer. It is well known that HPV positive 
HNSCC is associated with the sexual route of spread, particularly 
oral sex. (6,80–82) 
 
Co morbidities were seen in about half of the patients. This is most 
likely due to the higher age of most of the patients in the cohort. 
The co morbidities that were recorded were diabetes mellitus, 
hypertension, coronary artery disease, hypothyroidism and past 
history of tuberculosis. The second HPV positive patient who did 
not do well had a co morbidity of being a diabetic. There is some 
data that suggests that medical co morbidities may play a role in 
response to treatment.(83,84) Hess et al stated that HPV negative 
patients have a poorer response to treatment, not only because of 
their virological status but because HPV negative patients may be 
more older and would have more co morbidities leading to delays 
and interruptions of radiation therapy. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
LIMITATIONS 
 
 
 
 
 
 
 
 
 
Limitations 
 
The biggest limitation of this study was the scanty HPV positive 
patients in the sample pool with more of HPV negative patients. 
Statistical correlation, therefore, could not be made between the 2 
patients who were HPV positive and the 47 who were HPV 
negative.  
 
The follow up duration was less. Of the 49 patients who were 
analysed for HPV, only 41 patients had treatment. (8 patients left 
the institution without treatment) Of the 41 patients who underwent 
treatment, only 29 patients had any follow up, with a median follow 
up period of 3 months.  
 
In this study, only fresh tissue was used for HPV detection, and so 
needed a collection of sample from the patient even before 
histological diagnosis was confirmed. This also meant that consent 
for the same was taken before the patient had a confirmed diagnosis 
of cancer.  
 
The history of oral sex or multiple sex partners were not asked for 
in our cohort of patients. It is well known that HPV associated 
HNSCC is associated with oral sex/multiple sexual partners. 
(6,81,82). We tried to use a surrogate of the same, asking for a 
history of sexually transmitted disease, looking at HIV status, and 
asking for a history of previous anal or gynaecological malignancies 
(in particular carcinoma cervix). This was because of the sensitive 
nature of the questions that needed to be asked. Most western data 
where this association was proved used a self administered 
questionnaire to the patient and the data was anonymously collected 
thus facilitating the process. It also may have led to more accurate 
data being collected as patients may not reveal the correct nature of 
their activities when being asked for the same by an investigator 
filling a proforma. 
 
It would have been appropriate to look at other molecular markers 
that have shown good association with HPV positive HNSCC such 
as p16 and p53. (58) But this was not possible due to technical 
reasons. 
 
 
  
 
 
 
 
 
 
 
 
 
CONCLUSION 
 
 
 
 
 
 
 
 
 
 
Conclusions 
 
The survival assessment between HPV positive and negative 
cancers could not be made out because of the small number of HPV 
positive cancers as well as the short duration of follow up. 
 
Future research probably should look at only the oropharynx and 
tongue subsites in search of HPV positive cancers as these are the 
subsites which have shown high positivity in the Indian context. 
Also, in addition, the buccal mucosa subsite would be a worthy 
addition to the sites harbouring HPV (one of our patients who was 
HPV positive had a buccal mucosa primary). 
 
The association of oral submucous fibrosis with HPV was a chance 
finding in our study. This patient was also a regular tobacco chewer. 
This was the more probable reason for him to develop submucous 
fibrosis. Very sparse data is available on the association of HPV 
with submucous fibrosis in the literature. Future research needs to 
look at the association of HPV with oral pre malignant conditions 
like oral submucous fibrosis as well as other lesions such as 
leukoplakia and erythroplakia, all of which have traditionally been 
associated with tobacco and betel nut chewing. 
 
Among our patient cohort 78% were tobacco/alcohol users and this 
could probable be one of the reasons for the low rates of HPV 
detection in our study population. 
 
There is a need to look at the molecular profile like p16 and p53 in 
these patients as that is more significantly associated with 
prognosis.  
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APPENDIX 
 
 
 
 
Appendix 
 
ECOG Performance Score 
 
Grade ECOG 
0 Fully active, able to carry on all pre disease 
performance without restriction 
1 Restricted in physically strenuous activity but 
ambulatory and able to carry out work of a light or 
sedentary nature 
2 Ambulatory and capable of all self care but unable to 
carry out any work activities. Up and about more 
than 50% of waking hours 
3 Capable of only limited self care, confined to bed or 
chair more than 50% of waking hours 
4 Completely disabled. Cannot carry on any self care. 
Totally confined to bed or chair 
5 Dead 
 
Spread Sheet Of Data 
 
ser name hos no rt no age sex addres ph no 
1/13 Gulzar Khan 410300f 281/13/rt2 55 1 Vellore 822068311 
2/13 Riyaz Ahmed 397561b 49/13/rt2 48 1 Vellore 8220667504 
3/13 Bojraj 398209f nil 41 1 Chennai 9790754309 
4/13 Munniswamy 417419f 208/13/rt2 60 1 Vellore 9159160070 
7/13 Donapati Gosh 414758f 245/13/rt2 50 1 West Bengal 9475979897 
5/13 Sankar V 701163b 292/13/rt2 31 1 Vellore 9894544339 
8/13 Sapan Dey 268593f 278/13/rt2 47 1 West Bengal 9051216887 
9/13 Iman Ali 432094f 283/13/rt2 64 1 Assam 9954061861 
10/13 A. Kuppam 493729f 616/13/rt2 59 1 Thiruvanamalai 9944993727 
11/13 Bhuvanasundaram 491760f 545/13/rt2 63 1 Kuppam 9940761671 
12/13 Atma Ram Sharma 499374f 578/13/rt2 76 1 West Bengal 9830723769 
13/13 Subramani 275766f 623/13/rt2 64 1 Vellore 
 14/13 Dilip Kaur 494718f 
 
59 2 Jharkhand 7760684117 
15/13 Nitai Hait 608479f 672/13/rt2 57 1 West Bengal 9732816494 
16/13 Anisur Sahaji 600354f 653/13/rt2 25 1 West Bengal 9126060637 
17/13 Jayavathi Jesudoss 475707f 666/13/rt1 75 2 Tirupathur 9489335642 
18/13 Moidu K.K. 488070f 675/13/rt2 54 1 Kerala 9048817327 
19/13 Amiya kumar Sinha 648497f 762/13/rt2 63 1 West Bengal 9903323607 
20/13 Md Rukomazammen 645133f 756/13/rt2 49 1 Bangladesh 978625632 
21/13 Niranjan Debnath 668369f nil 47 1 West Bengal 9862437087 
22/13 Probir Mondal 670816f nil 47 1 West Bengal 
 23/13 Ali Hassan 706215f 58/14/r2 75 1 Kerala 9946170087 
24/13 Mehoronessa 723492f 28/14/rt1 63 2 Bangladesh 
 25/13 bhagyeshwar Patnagia 729689f 1038/13/rt2 54 1 Assam 9707556732 
26/13 benedith azuka 776721f 39/14/rt2 60 2 nigeria 9159093208 
27/13 Venkatesan a. s. 714758f 158/14/rt2 62 1 Vellore 
 28/13 Mosammet 770191f 104/14/rt2 62 2 Bangladesh 1718617905 
29/13 Gita Haran Sah 789934f 132/14/rt2 63 1 West bengal 1932169578 
30/13 Selva nalathambi 727627f nil 48 1 Ranipet 9894159623 
31/13 Ramamurthy R. 793849f 31/13 56 1 Vellore 9092117192 
32/13 Anil Chandra 794989f nil 64 1 Bangladesh 9600937926 
33/13 maadhu 778553f nil 40 1 Vellore 995239917 
34/14 Ishwer Kumar Singh 796563f Nil 58 1 Jharkhand 9934108861 
35/13 Apgani Begum 789601f 309/14/rt1 61 2 Assam 9854427994 
36/13 Jose VK 776863f nil 55 1 Kerala 9645654075 
37/13 Sarita Agarwal 790887f Nil 47 2 West Bengal 9434101651 
38/13 Bhipad Banjan 828094f Nil 65 1 West bengal 9647181165 
39/13 Saraswati Pandit 832213f Nil 78 2 West bengal 987453036 
40/13 Madhava Chakraborty 834803f 469/14/rt1 46 1 Bangladesh 974665811 
41/13 Rekha Aktar 806099f 375/14/rt1 49 2 Bangladesh 9.1842E+11 
42/13 Anjan Kumar Das 801865f 460/14/rt2 54 1 West Bengal 9434471445 
45/13 mantu Roy 803572f 403/14/rt1 48 1 West Bengal 9830505029 
46/13 Natesan V 502676d 580/14/rt2 70 1 Tiruvanamalai 
 47/13 Basubi Mondal 847120f 610/14/rt2 54 2 West Bengal 9748640909 
49/13 Johnson P. George 870018f 593/14/rt1 52 1 Kerala 949566551 
50/13 Saraswathy R. 865328f 609/14/rt2 60 2 Coimbatore 9944340056 
51/13 Sirajul Haque 867702f nil 56 1 Bangladesh 
 52/13 Naseem Ahmed 008846g Nil 54 1 West Bengal 9333462913 
53/13 Mithu Chandra 001468g nil 50 1 West Bengal 9474870770 
 
occupation educat dur symp smoking 
smokeless 
tobacco alcohol pre malig co morb sex tr dis 
1 1 2 TRUE FALSE FALSE FALSE TRUE FALSE 
1 1 1 TRUE FALSE FALSE FALSE TRUE FALSE 
4 1 3 TRUE FALSE TRUE FALSE TRUE TRUE 
1 1 3 TRUE FALSE TRUE FALSE FALSE FALSE 
2 1 9 TRUE TRUE FALSE FALSE FALSE FALSE 
1 1 3 FALSE TRUE FALSE FALSE TRUE FALSE 
1 1 9 TRUE TRUE FALSE FALSE FALSE FALSE 
2 1 6 TRUE TRUE FALSE FALSE FALSE FALSE 
2 1 3 TRUE FALSE TRUE FALSE FALSE FALSE 
1 1 2 TRUE FALSE TRUE FALSE FALSE FALSE 
4 1 4 TRUE TRUE FALSE FALSE TRUE FALSE 
1 1 12 TRUE FALSE TRUE FALSE FALSE FALSE 
3 1 3 FALSE FALSE FALSE FALSE TRUE FALSE 
2 1 8 TRUE TRUE TRUE FALSE FALSE FALSE 
2 1 7 FALSE TRUE FALSE FALSE FALSE FALSE 
3 1 3 FALSE TRUE FALSE FALSE TRUE FALSE 
1 1 4 TRUE FALSE FALSE FALSE TRUE FALSE 
1 2 6 TRUE TRUE TRUE FALSE TRUE FALSE 
4 1 2 TRUE TRUE FALSE FALSE TRUE FALSE 
4 1 7 FALSE TRUE FALSE TRUE FALSE FALSE 
1 1 5 FALSE TRUE FALSE FALSE TRUE FALSE 
1 1 3 TRUE TRUE FALSE TRUE FALSE FALSE 
1 1 2 FALSE TRUE FALSE FALSE FALSE FALSE 
1 1 12 FALSE FALSE FALSE FALSE FALSE FALSE 
4 3 6 FALSE FALSE FALSE FALSE FALSE FALSE 
1 1 6 TRUE FALSE TRUE FALSE FALSE FALSE 
3 1 3 FALSE TRUE FALSE FALSE TRUE FALSE 
4 2 6 TRUE FALSE FALSE FALSE TRUE FALSE 
4 3 1 FALSE FALSE FALSE FALSE TRUE FALSE 
1 1 2 TRUE FALSE TRUE FALSE TRUE FALSE 
1 1 5 TRUE TRUE FALSE FALSE TRUE FALSE 
1 1 3 FALSE TRUE TRUE FALSE FALSE FALSE 
1 1 3 TRUE FALSE FALSE FALSE FALSE FALSE 
3 1 3 FALSE TRUE FALSE FALSE TRUE FALSE 
4 2 2 FALSE TRUE TRUE FALSE TRUE FALSE 
3 1 3 FALSE FALSE FALSE FALSE FALSE FALSE 
  
3 FALSE FALSE FALSE FALSE FALSE FALSE 
3 1 5 FALSE FALSE FALSE FALSE FALSE FALSE 
  
3 FALSE TRUE FALSE FALSE TRUE FALSE 
3 1 18 FALSE FALSE FALSE FALSE FALSE FALSE 
4 1 3 FALSE TRUE FALSE FALSE TRUE FALSE 
1 1 24 TRUE TRUE TRUE FALSE FALSE FALSE 
1 1 1 FALSE FALSE FALSE FALSE TRUE FALSE 
3 1 3 FALSE TRUE FALSE FALSE FALSE FALSE 
4 1 3 TRUE FALSE TRUE FALSE TRUE FALSE 
3 1 3 FALSE TRUE FALSE FALSE FALSE FALSE 
1 1 6 FALSE FALSE FALSE FALSE TRUE FALSE 
1 1 6 FALSE TRUE FALSE FALSE FALSE FALSE 
1 1 2 FALSE FALSE FALSE FALSE FALSE FALSE 
 
pr malig PS site stage t n hb cr 
FALSE 1 2 4a 3 2 12.7 1.64 
FALSE 1 2 3 2 1 12.3 1.15 
FALSE 1 1 3 3 0 15.1 1.27 
FALSE 1 7 4a 4 2 15 0.96 
FALSE 1 1 4a 4 2 11.6 1.05 
FALSE 1 1 3 3 1 14.4 1.36 
FALSE 1 4 4b 4 1 12.3 1.15 
FALSE 1 6 4a 4 1 14.2 1.05 
FALSE 1 2 4a 3 2 14.1 0.84 
FALSE 1 8 4b 4 1 11.9 1.03 
FALSE 1 6 3 3 0 12.2 1.39 
FALSE 1 2 4a 4 2 14.2 0.83 
FALSE 1 1 1 1 0 10.5 1.73 
FALSE 1 2 4a 4 1 13.8 1.01 
FALSE 1 1 3 1 1 13.9 1.09 
FALSE 1 4 3 2 1 12 0.34 
FALSE 1 1 3 1 1 15.2 1.2 
FALSE 1 9 4a 3 2 14 1.18 
FALSE 1 2 3 2 1 14.9 1.19 
FALSE 1 4 1 1 0 14.2 1.11 
FALSE 1 5 1 1 0 13.7 0.96 
FALSE 1 5 4a 4 1 13.7 1.37 
FALSE 1 4 4a 1 2 12.7 0.89 
FALSE 1 9 4b 4 3 10.8 1.21 
FALSE 1 2 4a   1 10.9 0.69 
FALSE 1 1 2 2 1 15.5 0.79 
FALSE 1 1 3 3 0 15.4 1.18 
FALSE 1 2 4a 4 1 12.5 0.73 
FALSE 1 1 4 4 0 15.6 0.54 
FALSE 1 8 3 3 0 10.2 0.9 
FALSE 1 2 4a 3 2 13.2 1.18 
FALSE 1 4 4a 4 0 15.9 0.52 
FALSE 1 6 4a 4 2 15 0.87 
FALSE 1 4 4a 3 2 12 0.94 
FALSE 1 1 2 2 0 13.3 1.05 
FALSE 1 1 2 2 0 14.7 0.57 
FALSE 1 6 4a 2 2 
  FALSE 3 2 4a 4 2 12.3 1.4 
FALSE 1 2 4a 4 2 13.6 0.8 
FALSE 1 1 3 2 1 12.6 0.6 
FALSE 1 1 2 2 0 9.4 3.06 
FALSE 1 1 3 2 1 13.5 1.07 
FALSE 1 2 4b 3 3 12.8 1.27 
FALSE 1 4 4a 4 2 11.8 0.65 
FALSE 1 3 1 1 0 12 0.62 
FALSE 1 1 2 2 0 13.1 0.67 
FALSE 1 1 1 1 0 15.1 0.84 
FALSE 1 5 4a 4 0 11.7 0.88 
FALSE 1 1 3 2 1 13.3 0.97 
 
surgery rt ch rt rt breaks hpv e6 e7 p16 residual 
FALSE TRUE FALSE FALSE FALSE 0 FALSE TRUE 
FALSE TRUE FALSE FALSE FALSE 0 FALSE FALSE 
TRUE FALSE FALSE FALSE FALSE 0 FALSE FALSE 
FALSE TRUE FALSE FALSE FALSE 0 FALSE FALSE 
FALSE FALSE TRUE FALSE FALSE 0 FALSE FALSE 
FALSE TRUE FALSE TRUE FALSE 0 FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE 0 FALSE FALSE 
FALSE FALSE TRUE FALSE FALSE 0 FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE 0 FALSE FALSE 
FALSE TRUE FALSE FALSE FALSE 0 FALSE FALSE 
FALSE TRUE FALSE TRUE FALSE 0 FALSE FALSE 
FALSE TRUE FALSE FALSE FALSE 0 FALSE FALSE 
TRUE FALSE FALSE FALSE FALSE 0 FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE 0 FALSE FALSE 
TRUE TRUE FALSE TRUE FALSE 0 FALSE FALSE 
TRUE TRUE FALSE TRUE FALSE 0 FALSE FALSE 
TRUE TRUE FALSE FALSE FALSE 0 FALSE FALSE 
FALSE FALSE TRUE FALSE FALSE 0 FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE 0 FALSE FALSE 
TRUE FALSE FALSE FALSE TRUE 0 FALSE FALSE 
TRUE FALSE FALSE FALSE FALSE 0 FALSE FALSE 
TRUE TRUE FALSE TRUE FALSE 0 FALSE FALSE 
TRUE TRUE FALSE FALSE FALSE 0 FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE 0 FALSE FALSE 
FALSE FALSE TRUE FALSE FALSE 0 FALSE TRUE 
TRUE TRUE FALSE FALSE FALSE 0 FALSE FALSE 
TRUE TRUE FALSE TRUE FALSE 0 FALSE FALSE 
FALSE TRUE FALSE FALSE FALSE 0 FALSE FALSE 
TRUE FALSE FALSE FALSE FALSE 0 FALSE FALSE 
FALSE FALSE TRUE TRUE TRUE 0 FALSE TRUE 
FALSE TRUE FALSE FALSE FALSE 0 FALSE TRUE 
TRUE FALSE TRUE FALSE FALSE 0 FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE 0 FALSE FALSE 
TRUE TRUE FALSE TRUE FALSE 0 FALSE FALSE 
TRUE FALSE FALSE FALSE FALSE 0 FALSE FALSE 
TRUE FALSE FALSE FALSE FALSE 0 FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE 0 FALSE FALSE 
FALSE FALSE FALSE FALSE FALSE 0 FALSE FALSE 
FALSE TRUE FALSE FALSE FALSE 0 FALSE TRUE 
TRUE TRUE FALSE TRUE FALSE 0 FALSE FALSE 
TRUE TRUE FALSE FALSE FALSE 0 FALSE FALSE 
TRUE TRUE FALSE FALSE FALSE 0 FALSE FALSE 
FALSE TRUE FALSE TRUE FALSE 0 FALSE FALSE 
TRUE FALSE FALSE FALSE FALSE 0 FALSE FALSE 
TRUE TRUE FALSE FALSE FALSE 0 FALSE FALSE 
TRUE TRUE FALSE TRUE FALSE 0 FALSE FALSE 
TRUE FALSE FALSE FALSE FALSE 0 FALSE FALSE 
TRUE FALSE FALSE FALSE FALSE 0 FALSE FALSE 
TRUE FALSE FALSE FALSE FALSE 0 FALSE FALSE 
 
ti loc 
ti 
reg 
ti 
met 
ti 
death tot fol up 
3 1 3 3 3 
3 6 6 6 6 
    
0 
3 3 6 6 6 
3 4 4 4 4 
3 6 6 6 6 
    
0 
12 12 12 12 12 
    
0 
6 6 6 6 6 
3 3 3 3 3 
9 9 9 9 9 
12 12 12 12 12 
    
0 
3 4 4 4 4 
9 9 9 9 9 
12 12 12 12 12 
10 9 9 10 10 
    
0 
6 6 6 6 6 
9 9 9 9 9 
3 3 3 3 3 
3 3 3 3 3 
    
0 
    
0 
3 3 3 3 3 
3 3 3 3 3 
    
0 
    
0 
2 3 3 3 3 
1 3 3 3 3 
3 3 3 3 3 
    
0 
4 3 4 4 4 
6 6 6 6 6 
3 3 3 3 3 
    
0 
    
0 
1 1 1 1 1 
3 3 3 3 3 
    
0 
3 3 3 3 3 
    
0 
    
0 
    
0 
    
0 
    
0 
    
0 
    
0 
 
 
 
 
 
 
 
 
Protocol Flow Chart 
 
 
 
 
 
Study Proforma  
                                                              PATIENT ID:  
 
Name:     Hosp.No.  R.T. No. 
Age :     DOB:    Sex: 
Address:     . 
 Local      Permanent 
 
  
 Ph no      Ph no 
 
Marital Status 
 
Socioeconomic status:   1. Patient’s Occupation: 
     2. Patient’s Education   : 
 
Presenting complaints: 
      Duration 
Throat pain           Y/N  
Dysphagia(liquids/semisolids/solids)  Y/N 
Ulcer       Y/N 
Bleeding      Y/N 
Hoarseness     Y/N  
Cough       Y/N 
Stridor      Y/N 
Neck swelling:     Y/N 
Headache:     Y/N 
Trismus:     Y/N 
Ear Ache:     Y/N 
Others:       
Addictions:  
1.  Smoking  Y/N Packs  per day-     Duration -      
/yrs  
 
2. Smokeless Tobacco       Y/N               Duration -      
/yrs       
   
3. Alcohol     Y/N          Amount & frequency -   Duration -       /yrs        
      
Associated diseases:   Premalignant conditions    
    Leukoplakia 
    Erythroplakia 
    Submucous Fibrosis 
    Dysplasia 
     DM/ HT/ TB/ Others 
    Allergies  
    Sexually Transmitted Diseases               
   
Past history:   Previous Oral/Anal/Gynaecological 
malignancies 
GENERAL EXAMINATION: 
 
Performance status: ECOG        
Physical parameters :Weight-  Height-      BSA- 
Vitals   :BP-       PR- 
Pallor/ Icterus/ Edema /  
Tracheostomy / Ryle’s tube 
Systemic examination:  CVS 
    RS 
    Abdomen 
Local examination                
 
 
                                            
 
                              
        
 
Oral Cavity 
 Lip Buccal 
Mucosa 
Tongue Upper 
Alveolus 
Lower 
Alveolus 
Hard Palate Floor of 
Mouth 
Size        
Nature         
Others        
 
Oropharynx 
 Base Of Tongue Tonsil Posterior pharyngeal 
wall 
Uvula and Soft 
Palate 
Size     
Nature     
Others     
 
NPL scopy /IDL  
 
 
 
 
 
 
 
 
 
 
 Neck-  
Lymph nodes-Y/N 
Side Level no Size 
Mobile/ 
Fixed 
Discrete/ 
Matted 
Skin –Free/ 
Tethered 
Ulcerated 
right 
1      
2      
3      
4      
5      
left 
1      
2      
3      
4      
5      
 
 
Clinical Diagnosis: 
 
Site:     T         N         M                   Stage: 
 
 
 
INVESTIGATIONS 
 
 
Haemogram (date:           ) HB-    TC-  DC - 
 Platelets- 
                 
Biochemistry  (date:           ) Creatinine-  
 Creatinine clearance – 
    LFT-  
                             
Virology        (date:            )  HIV-  HCV-  HbsAg- 
        
Chest xray     (date:            ) - 
 
 
CT scan (date:           ) - 
Histopathology Biopsy No (                /         )-    
(date:            )   Squamous cell carcinoma  
 
 
FNAC:    Site -     Report - 
 (date:            )    
    
 
Post op Histopathology Biopsy No (                /         )-   
(date:            )   Squamous cell carcinoma  
   Well / moderately / poorly differentiated 
   Size 
Margins –  
    
Lymph nodes: No-             
extracapsular invasion: Y/N 
   Lymphatic / vascular invasion - Y/N 
   p 
 
 
Final diagnosis 
Site     T  N 
 M    Stage           
Sub Site 
 
Any other details:    
 
 
 
 
 
 
 
 
TREATMENT DETAILS:  
Primary Radical Surgery followed by Post Op RT 
Primary Radical Surgery followed by Post Op 
Chemoirradiation 
Primary Radical Radiotherapy 
Primary Radical Radiotherapy followed by Salvage 
Surgery 
Primary Radical Radiotherapy with concurrent 
chemotherapy followed by Salvage Surgery 
Primary Radical Radiotherapy with concurrent biological 
therapy 
Palliative Radiotherapy 
 
Overall treatment time: 
 
Date started: 
Date completed: 
 
Machine: Co 60 / 6X  
 
Dose 
Fractions / week: 
Technique: 
TD / # 
 
 
 
 
  
 Treatment Break  Yes/No   
No of breaks Duration  in days Reason 
1   
2   
3   
4   
 
 
 
 
HPV STATUS 
Genotype 16/18 –    
 
E6/E7 RNA quantification:                   copies/ml 
 
 
p16 STATUS 
 
Positive / Negative 
 
 
 
DETAILED FOLLOW UP 
PLAN  
 
 
1ST FOLLOW UP AT 6 WEEKS: 
 1. HISTORY AND PHYSICAL EXAMINATION  
2. NPL SCOPY (OROPHARYNGEAL)  
3. POST RT ASSESSMENT 
 
 
 
 
 
 
2ND FOLLOW UP AT 3 MONTHS: 
1. HISTORY AND PHYSICAL EXAMINATION  
2. NPL SCOPY (OROPHARYNGEAL)  
3. POST RT ASSESSMENT 
 
 
 
 
 
 3RD FOLLOW UP AT 6 MONTHS: 
1. HISTORY AND PHYSICAL EXAMINATION  
2. NPL SCOPY (OROPHARYNGEAL)  
3. CHEST XRAY 
 
 
 
 
 
 
 
 
 
4TH FOLLOW UP AT 9 MONTHS: 
1. HISTORY AND PHYSICAL EXAMINATION  
2. NPL SCOPY (OROPHARYNGEAL)  
 
 
 
 
 
 
 
5TH FOLLOW UP AT 12 MONTHS: 
1. HISTORY AND PHYSICAL EXAMINATION 
2. NPL SCOPY (OROPHARYNGEAL)  
3. CHEST XRAY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Informed Consent 
 
Christian Medical College, Vellore 
Department of Radiotherapy Unit 2 
Disease Outcome in Oral and Oropharyngeal 
Squamous Cell Cancers based on Combined 
Virological and Molecular Risk Stratification. (HPV 
HNRS STUDY) 
Patient Information sheet 
You are being asked to take part in a study to find out whether 
outcome of your disease is affected by certain additional tests (HPV 
and p16) which will be done on the mandatory diagnostic biopsy. 
If you decide to take part, what will you have to do?  
You would be asked to answer a few questions about yourself, your 
habits and other personal details. Also, in addition to the biopsy 
taken to confirm the disease, an additional small amount of tissue 
would be sent for special testing. There is no need to worry about 
this because this tissue would be removed at the time of the 
diagnostic biopsy. There would be no additional cost to you, except 
that which you would otherwise pay for a normal biopsy. Once your 
treatment is completed, you would be expected to come for regular 
checkups to check on your disease status. The additional tests 
would be performed only after the diagnostic biopsy report is ready. 
If the diagnostic biopsy is inconclusive for cancer, no special tests 
would be done and you would be informed of the same. You would 
also be asked to undergo a repeat biopsy at that time to confirm the 
disease.  
There is a chance that the biopsy report shows a rare type of cancer 
which is not associated with the additional tests that are performed. 
In that case also, the tests would not be done and you would be 
informed of the same. 
Can you withdraw from this study after it starts? 
Your participation in this study is entirely voluntary and you are 
free to decide to withdraw permission to participate in this study. If 
you decide to do so, this would not affect your usual treatment at 
this hospital in any way. .  
Will you have to pay for the extra tests?  
As explained above, you would have to pay for the mandatory 
diagnostic biopsy prior to the diagnosis of cancer, but the extra tests 
would be done without any cost to you. 
What happens after the study is over? 
The results of this study may not benefit you directly but it would 
definitely help to design better treatments for people with similar 
problems in the future.  
 
Will your personal details be kept confidential? 
The results of this study may be published in a medical journal but 
you would not be identified by name in any publication or 
presentation of results. However, your medical notes may be 
reviewed by people associated with the study, without your 
additional permission, if you decide to participate in this study.  
 
If you have any further questions, please ask  
Dr. Andrew C. Fenn 
Dept Of Radiotherapy Unit 2 
CMC, VELLORE 
andrew_fenn@rediffmail.com 
CONSENT TO TAKE PART IN A CLINICAL TRIAL 
 
Study Title: Disease Outcome in Oral and Oropharyngeal 
Squamous Cell Cancers based on Combined Virological and 
Molecular Risk Stratification (HPV HNRS) 
 
Study Number: 
Participant’s name:  
 
Date of Birth / Age (in years): 
 
I______________________________________________________
_______,   
son/daughter/wife of  
____________________________________________ 
(Please tick boxes) 
Declare that I have read the information sheet provide to me 
regarding this study and have clarified any doubts that I had. [     
] 
I also understand that my participation in this study is entirely 
voluntary and that I am free to withdraw permission to 
continue to participate at any time without affecting my usual 
treatment or my legal rights [      ] 
I understand that the study staff and institutional ethics 
committee members will not need my permission to look at my 
health records even if I withdraw from the trial. I agree to this 
access   [     ]  
I understand that my identity will not be revealed in any 
information released to third parties or published [      ]   
I voluntarily agree to take part in this study [      ] 
 
Name: 
 
Signature/ Thumb Impression: 
 
Date: 
 
 
Name of witness: 
 
Relation to participant: 
 
Date: 
 
 
 
 
 
 
 
 
Glossary of Terms 
 
HPV – Human Papilloma Virus 
LR HPV – Low Risk Human Papilloma Virus 
HR HPV – High Risk Human Papilloma Virus 
HR HPV ISH – High Risk Human Papilloma Virus In Situ 
Hybridisation 
p16 – D-type cyclin-dependent kinase 
ENT – Ear, Nose and Throat 
RT – Radiotherapy  
DNA – Deoxy Ribonucleic Acid 
RNA – Ribonucleic Acid 
PCR – Polymerase Chain Reaction 
HNSCC – Head and Neck Squamous Cell Cancers 
RCT – Randomized Control Trial 
NPL Scopy – Naso Pharyngo Layngoscopy 
TNM – Tumour Node Metastasis 
ECOG – Eastern Co-operative Oncology Group 
 
